Share on StockTwits

Cubist Pharmaceuticals (NASDAQ:CBST) SVP Gregory Stea unloaded 38,326 shares of the company’s stock on the open market in a transaction dated Tuesday, August 19th. The shares were sold at an average price of $65.88, for a total transaction of $2,524,916.88. Following the transaction, the senior vice president now directly owns 18,136 shares in the company, valued at approximately $1,194,800. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

CBST has been the subject of a number of recent research reports. Analysts at Zacks downgraded shares of Cubist Pharmaceuticals from a “neutral” rating to an “underperform” rating in a research note on Monday. They now have a $58.00 price target on the stock. Separately, analysts at JMP Securities downgraded shares of Cubist Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research note on Wednesday, July 23rd. They now have a $80.00 price target on the stock. Finally, analysts at Aegis reiterated a “positive” rating on shares of Cubist Pharmaceuticals in a research note on Monday, June 23rd. One analyst has rated the stock with a sell rating, three have given a hold rating and nine have issued a buy rating to the company. The stock presently has an average rating of “Buy” and an average price target of $79.64.

Shares of Cubist Pharmaceuticals (NASDAQ:CBST) traded up 0.80% during mid-day trading on Friday, hitting $65.44. The stock had a trading volume of 112,055 shares. Cubist Pharmaceuticals has a 52 week low of $58.50 and a 52 week high of $82.12. The stock’s 50-day moving average is $64.12 and its 200-day moving average is $69.30. The company has a market cap of $4.956 billion and a P/E ratio of 569.47.

Cubist Pharmaceuticals (NASDAQ:CBST) last released its earnings data on Tuesday, July 22nd. The company reported $0.23 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.01 by $0.22. The company had revenue of $294.40 million for the quarter, compared to the consensus estimate of $299.60 million. During the same quarter in the prior year, the company posted $0.42 earnings per share. The company’s quarterly revenue was up 13.8% on a year-over-year basis. On average, analysts predict that Cubist Pharmaceuticals will post $0.71 earnings per share for the current fiscal year.

Cubist Pharmaceuticals, Inc (NASDAQ:CBST) is a biopharmaceutical company focused on the research, development and commercialization of therapies to treat serious medical conditions in acutely ill patients who are hospitalized or are being treated in other acute care settings.

Receive News & Ratings for Cubist Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cubist Pharmaceuticals Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.